Globus Medical Inc. (NYSE: GMED) upgraded to Buy by Needham with a $112 price target on January 30, following positive Q4 revenue announcement. Needham cites expanding EBITDA margins and potential for increased organic revenue growth as key factors driving improved earnings expectations for 2026.

TD Cowen initiates coverage on Globus with a Buy rating and $110 price target, noting potential for further outperformance. Opportunities for growth include progress in the Nevro business segment, expansion into international markets, and enabling technologies. Historical share performance and financial strength are also supportive factors.

Globus Medical Inc. (NYSE: GMED) develops and commercializes medical devices for musculoskeletal disorders, including implantable devices, biologics, and surgical instruments for spinal, orthopedic trauma, and joint reconstruction procedures. The company is seen as one of the best medical technology stocks to invest in.

While GMED shows promise as an investment, some AI stocks may offer greater upside potential with less downside risk. Investors seeking opportunities in the AI sector may benefit from exploring undervalued stocks that stand to gain from current economic trends.

Read more at Yahoo Finance: Globus Medical Inc. (GMED) Gains Positive Attention Amid Improving Outlook